EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Antigen-specific profiling identifies T-bet+ melanoma-specific CD8+ T cells associated with response to neoadjuvant PD-1 blockade

Guanning Wang, Daniel Yoon, Ajeya Nandi, Khushboo Patel, Tarek Azar, Justin Kim, Nicholas A Han, Aaron Nickie, Stella Park, Kevin Wang, Patrick Yan, Shraya Divaker und 18 weitere

Cancer Cell · 2026

DOI: 10.1016/j.ccell.2025.12.004 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Cell, 2026. Verfasst von Guanning Wang und 29 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Immune Checkpoint Inhibitors, Melanoma, Nivolumab. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, W W Smith Charitable Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite widespread immune profiling in cancer immunotherapy, the antigen-specific responses that drive clinical outcomes remain poorly defined. In a prospective neoadjuvant trial (NCT04013854) of a single-dose anti-PD-1 (nivolumab) in stage III melanoma, we performed antigen-specific profiling of melanoma and viral-specific CD8+ T cells across blood, tumor, and lymph node compartments. Using combinatorial tetramers, we detected melanoma-specific CD8+ T cells in 72% of HLA-A1, -A2, and -A3 patients. These cells displayed distinct phenotypes shaped by tissue and antigen context. Tumor-infiltrating T-bet+ intermediate exhausted CD8+ T cells were strongly associated with pathologic response, while CD39+ terminal exhausted cells marked non-response. T-bet and CD39 expression also stratified responses in uninvolved lymph nodes, suggesting early divergence of therapeutic immune trajectories. Longitudinal profiling revealed that circulating melanoma-specific CD8+ T cell dynamics was antigen-dependent and associated with clinical outcomes. Our findings highlight the clinical value of antigen-specific profiling and identify mechanistic correlates of anti-PD-1 efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesImmune Checkpoint InhibitorsMelanomaNivolumabProgrammed Cell Death 1 ReceptorSkin NeoplasmsT-Box Domain ProteinsFemaleHumansMaleMiddle AgedAntigens, NeoplasmApyraseLymphocytes, Tumor-InfiltratingNeoadjuvant TherapyProspective StudiesT-bet Transcription Factor

Stichwörter der Autor:innen

CD8 T cell reinvigorationPD-1 blockadeantigen-specific CD8 T cellsbiomarkerexhausted T cellsexhausted subsetsimmune checkpointimmune profilinglymph nodeneoadjuvant

Substanzen

Antigens, NeoplasmApyraseImmune Checkpoint InhibitorsNivolumabPDCD1 protein, humanProgrammed Cell Death 1 ReceptorT-bet Transcription FactorT-Box Domain Proteins

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
  • Tara Miller Melanoma Center, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Department of Systems Pharmacology & Translational Therapeutics, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology and Immune Health, Philadelphia, PA, USA.
  • Clinical Immunology Laboratory, Institut Curie, Paris, France; Université Paris Cité, INSERM, PARCC, 75015 Paris, France.

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • W W Smith Charitable Trust
  • Perelman School of Medicine, University of Pennsylvania
  • National Institutes of Health
  • Damon Runyon Cancer Research Foundation
  • PEW Charitable Trusts
  • Tara Miller Melanoma Foundation

Zitieren

APA

Wang, G., Yoon, D., Nandi, A., Patel, K., Azar, T., Kim, J., Han, N. A., Nickie, A., Park, S., Wang, K., Yan, P., Divaker, S., Tabita-Martinez, J., Giles, L., Carberry, M., Beltra, J. C., Painter, M. M., Alanio, C., Amaravadi, R. K., …, & Huang, A. C. (2026). Antigen-specific profiling identifies T-bet+ melanoma-specific CD8+ T cells associated with response to neoadjuvant PD-1 blockade. Cancer Cell. https://doi.org/10.1016/j.ccell.2025.12.004

Vancouver

Wang G, Yoon D, Nandi A, Patel K, Azar T, Kim J, et al. Antigen-specific profiling identifies T-bet+ melanoma-specific CD8+ T cells associated with response to neoadjuvant PD-1 blockade. Cancer Cell. 2026. doi:10.1016/j.ccell.2025.12.004

BibTeX
@article{Wang2026,
  author = {Wang, Guanning and Yoon, Daniel and Nandi, Ajeya and Patel, Khushboo and Azar, Tarek and Kim, Justin and Han, Nicholas A and Nickie, Aaron and Park, Stella and Wang, Kevin and Yan, Patrick and Divaker, Shraya and Tabita-Martinez, Jennifer and Giles, Lydia and Carberry, Mary and Beltra, Jean Christophe and Painter, Mark M and Alanio, Cecile and Amaravadi, Ravi K and Schuchter, Lynn M and Carreno, Beatriz M and Linette, Gerald P and Elder, David E and Brody, Robert M and Gimotty, Phyllis and Miura, John T and Karakousis, Giorgos C and Xu, Xiaowei and Mitchell, Tara C and Huang, Alexander C},
  title = {Antigen-specific profiling identifies T-bet+ melanoma-specific CD8+ T cells associated with response to neoadjuvant PD-1 blockade},
  journal = {Cancer Cell},
  year = {2026},
  doi = {10.1016/j.ccell.2025.12.004}
}
Kostenlos starten →